ReferenceCitation: du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16.

family: du Bois

full_name: Andreas du Bois

given: Andreas

family: Kristensen

full_name: Gunnar Kristensen

given: Gunnar

family: Ray-Coquard

full_name: Isabelle Ray-Coquard

given: Isabelle

family: Reuss

full_name: Alexander Reuss

given: Alexander

family: Pignata

full_name: Sandro Pignata

given: Sandro

family: Colombo

full_name: Nicoletta Colombo

given: Nicoletta

family: Denison

full_name: Ursula Denison

given: Ursula

family: Vergote

full_name: Ignace Vergote

given: Ignace

family: del Campo

full_name: Jose M del Campo

given: Jose M

family: Ottevanger

full_name: Petronella Ottevanger

given: Petronella

family: Heubner

full_name: Martin Heubner

given: Martin

family: Minarik

full_name: Thomas Minarik

given: Thomas

family: Sevin

full_name: Emmanuel Sevin

given: Emmanuel

family: de Gregorio

full_name: Nikolaus de Gregorio

given: Nikolaus

family: Bidziński

full_name: Mariusz Bidziński

given: Mariusz

family: Pfisterer

full_name: Jacobus Pfisterer

given: Jacobus

family: Malander

full_name: Susanne Malander

given: Susanne

family: Hilpert

full_name: Felix Hilpert

given: Felix

family: Mirza

full_name: Mansoor R Mirza

given: Mansoor R

family: Scambia

full_name: Giovanni Scambia

given: Giovanni

family: Meier

full_name: Werner Meier

given: Werner

family: Nicoletto

full_name: Maria O Nicoletto

given: Maria O

family: Bjørge

full_name: Line Bjørge

given: Line

family: Lortholary

full_name: Alain Lortholary

given: Alain

family: Sailer

full_name: Martin Oliver Sailer

given: Martin Oliver

location_country:
Finland
Greece
Australia
Belgium
Russian Federation
Denmark
Ukraine
France
Poland
Slovakia
Norway
Canada
Sweden
Netherlands
Portugal
United States
Germany
United Kingdom
Italy
Austria
Czechia
Spain

acronym: BIBF 1120 or placebo in combination with standard chemotherapy in advanced ovarian cancer

location_facility: 1199.15.44005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.61006 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39037 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10110 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10112 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10012 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.32012 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49080 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.47002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.43005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10028 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.46001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.42003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49095 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49021 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.44006 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49043 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49070 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49066 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49082 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.35101 Instituto Portugues de Oncologia Lisboa Francisco Gentil

location_facility: 1199.15.10113 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10013 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10024 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33047 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.32010 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49017 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39020 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.42103 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.38002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.44003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33006 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49031 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49008 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10020 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33045 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.43002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49076 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49010 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49055 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.31006 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.34009 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.42105 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.38006 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49040 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.43003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.32001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10021 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33051 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.30005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.45001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.42002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.46005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.44008 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.31003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49027 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49018 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49048 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33011 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49087 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10030 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49045 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.61001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39023 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.38005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49016 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49058 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10016 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.45003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39030 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.30003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.44007 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.48001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49050 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.42106 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49025 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10102 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.70006 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.46004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.46003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39034 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.42101 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.31005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49030 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49089 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10011 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10103 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33037 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49007 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39013 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10105 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10100 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33020 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.30001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49029 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39014 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.44004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10108 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.47003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.70007 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49014 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.42001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39018 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39032 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.48006 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10017 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.61004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.61005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49092 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.38003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33048 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49006 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49061 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.43012 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39039 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.35106 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49035 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.35109 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33055 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.35108 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10010 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49086 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.44002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33012 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.70001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49062 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.34003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49073 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49081 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49063 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10104 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.43001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49022 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.47004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33042 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39026 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.45005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49079 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.35102 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10014 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39012 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49019 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49064 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.38004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.30004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.31002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33008 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39021 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.70005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33052 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10019 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49026 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10006 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49083 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49009 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39028 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39011 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33031 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49033 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33025 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.42104 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49023 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49034 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.42102 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.31004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.45002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.30002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.48003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.32007 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.35804 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49054 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49060 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39027 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.11001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49015 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49024 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39009 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39036 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.11004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.11008 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49011 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.70002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.35801 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49056 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39006 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49093 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33035 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33013 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49037 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.11003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.11006 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.43010 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49036 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.61003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.32008 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39029 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39022 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.44001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.11009 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49039 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.61007 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33021 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49046 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33027 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49084 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49065 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10029 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33033 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33039 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10008 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49020 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49051 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39040 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39008 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39024 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.34006 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33009 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49059 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49042 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49071 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.34004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49090 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.35104 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49052 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33030 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.43013 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49041 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.61002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.35105 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.35805 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49085 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39031 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.43007 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.31009 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49067 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39007 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10107 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.35803 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.45004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49057 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49047 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10007 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39033 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33018 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.34001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.34010 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39019 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33038 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33015 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39017 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.39010 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49068 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.32003 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.11005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.47001 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.46002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33053 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.49012 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33004 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.34002 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.34005 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.33050 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.35802 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.10025 Boehringer Ingelheim Investigational Site

location_facility: 1199.15.43011 Boehringer Ingelheim Investigational Site

title: Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

summary: The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.


type: EudraCT Number

title: Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

summary: The primary objective is to evaluate the long-term safety and tolerability of aducanumab after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).

study_start_date_type: Actual

status: Active, not recruiting

study_completion_date_type: Anticipated

study_type: Interventional

primary_purpose: Treatment

enrollment_type: Actual

ipd_sharing: Yes

ipd_sharing_description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/

lead_sponsor: Biogen

location_country:
Italy
Austria
United States
Sweden
Switzerland
Netherlands
Spain
Germany
Finland
France
Japan
Poland
Australia
Belgium
Portugal
Denmark
Canada
United Kingdom
Korea, Republic of
Taiwan

location_facility: Neuropsychiatric Research Center of Southwest Florida

location_facility: Northeastern Pennsylvania Memory and Alzheimer's Center

location_facility: NZOZ "NEURO-KARD", "Ilkowski i Partnerzy" Sp. Partn. Lek.

location_facility: A.O.U. Senese Policlinico Santa Maria alle Scotte

location_facility: Josephson, Wallack, Munshower Neurology, P.C.

location_facility: Advanced Memory Research Inst. of NJ, PC

location_facility: Ascension Via Christi Research, a division of Ascension Via Christi Hospitals Wichita, Inc.

location_facility: Centro Hospitalar e Universitário de Coimbra E.P.E - Hospitais da Universidade de Coimbra

location_facility: The National Hospital for Neurology and Neurosurgery Centre

location_facility: Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza

location_facility: NZOZ Wroclawskie Centrum Alzheimerowskie

location_facility: Christian-Doppler-Klinik - Universitätsklinikum Salzburg

location_facility: Georgetown University Clinical Research Unit (CRU)

location_facility: Mary S. Easton Center for Alzheimer's Disease Research, UCLA

location_facility: CHU de Lyon - Hopital Neurologique Pierre Wertheimer

location_facility: Toronto Memory Program (Neurology Research Inc.)

location_facility: AOU dell'Università degli studi della Campania Luigi Vanvitelli

location_facility: University of Kansas Medical Center Research Institute, Inc.

location_facility: Gastroenterology Associates of the Piedmont

location_facility: Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC)

location_facility: University of California San Diego Medical Center

location_facility: Changhua Christian Medical Foundation Changhua Christian Hospital

location_facility: Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi D'Aragona

location_facility: Azienda Ospedaliera e Universitaria di Perugia

location_facility: Australian Alzheimer's Research Foundation

location_facility: National Clinical Research Inc.-Richmond

location_facility: Klinikum rechts der Isar der TU Muenchen

location_facility: Emory University Cognitive Neurology Clinic & ADRC

location_facility: Ohio State University Wexner Medical Center

location_facility: California Neuroscience Research Medical Group Inc.

location_facility: Alexian Brothers Medical Center - Neuroscience Research Institute

location_facility: Institut fuer Schlaganfall- und Demenzforschung (ISD)

location_facility: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

location_facility: Centre Hospitalier Universitaire Vaudois

location_facility: Charite Universitaetsmedizin Berlin - Campus Berlin Buch

location_facility: Azienda Ospedaliero Universitaria Pisana

location_facility: New York University Medical Center PRIME

location_facility: University of Utah Health Sciences Center

location_facility: Research Center for Clinical Studies, Inc.

location_facility: Medical Research Health and Education Foundation, Inc

location_facility: Azienda Ospedaliero Universitaria San Martino

location_facility: SPZOZ Centralny Szpital Kliniczny UM w Lodzi

location_facility: Lehigh Center for Clinical Research, LLC

location_facility: Seoul National University Bundang Hospital

location_facility: Montreal Neurological Institute Clinical Research Unit

location_facility: Kawartha Centre - Redefining Healthy Aging

location_facility: Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie

location_facility: Hospital Universitari i Politecnic La Fe

location_facility: Studienzentrum fur Neurologie und Psychiatrie

location_facility: Cleveland Clinic Lou Ruvo Center for Brain Health

location_facility: Sahlgrenska Universitetssjukhuset, Mölndal Sjukhus

location_facility: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)

location_facility: Medical University of South Carolina (MUSC)

location_facility: University of Calgary - Heritage Medical Research Clinic

location_facility: CHU de Quebec - Hôpital de l' Enfant Jésus

location_facility: Neuro Centrum Science GmbH, Geschaftführende Gesellschafterin Barbara Unsorg und Prüfarzt Dr. med. G

location_facility: Rhode Island Mood & Memory Research Institute

location_facility: Fondazione IRCCS Istituto Neurologico Carlo Besta

location_facility: Brigham and Women's Hospital Department of Neurology

location_facility: Jacksonville Center for Clinical Research

location_facility: Central Coast Neurosciences Research (Erina)

location_facility: Queen Elizabeth University Hospital Campus

location_facility: Groupe Hospitalier Pellegrin - Hôpital Pellegrin

location_facility: ISPG - Institut fuer Studien zur Psychischen Gesundheit

location_facility: True North Clinical Research - Halifax Inc.

location_facility: Zentrum f. Neurologisch- Psychiatrische Studien und Begutachtung

location_facility: Institut fur Regenerative Medizin-IREM Universitat Zurich, Campus Schlieren

intervention_type: Drug

lead_sponsor_type: industriel

status_simplified: Ongoing


design_allocation: Randomized

status: Recruiting

lead_sponsor: ImmunoGen, Inc.

enrollment_type: Anticipated

location_country:
Belgium
Australia
Russian Federation
Taiwan
Ukraine
France
Poland
Canada
Korea, Republic of
Netherlands
Bulgaria
China
Portugal
United States
Germany
United Kingdom
Italy
Serbia
Czechia
Israel
Spain

acronym: MIRASOL

location_facility: The Ohio State University Wexner Medical Center

location_facility: National Cancer Center - Center for Uterine Cancer

location_facility: BIH of Omsk Region "Clinical Oncology Dispensary"

location_facility: Florida Cancer Specialist North Division

location_facility: Tennessee Oncology / Sarah Cannon Research Institute

location_facility: St Bartholomew's Hospital-Barts Health NHS Trust

location_facility: USOR: Arizona Oncology Associates, PC - HOPE

location_facility: Institut de cancérologie de l'ouest, site Angers

location_facility: USOR: Maryland Oncology Hematology, P.A.

location_facility: Communal non-profit enterprise "Khmelnytskyi Regional Antitumor Center" of Khmelnytskoyi Regional Council

location_facility: Chernihiv Medical Center of Modern Oncology of Chernihiv Regional Council

location_facility: USOR: OHC - Oncology_Hematology Care Clinical Trials, Inc.

location_facility: Centre Hospitalier de L'Universite de Montreal

location_facility: Centre Hospitalier Universitaire de Sherbrooke

location_facility: Groupe Hospitalier Diaconesses Croix Saint-Simon

location_facility: Royal Devon and Exeter Hospital (Wonford)

location_facility: USOR: Texas Oncology - Fort Worth Cancer Center

location_facility: Arizona Oncology Associates, PC - HAL - USOR

location_facility: University of Ulsan College of Medicine - Asan Medical Center

location_facility: Oncologia Azienda Osc-IRCCS Reggio Emilia

location_facility: Kaiser Permanente Oncology Clinical Trials

location_facility: Women & Infants Hospital of Rhode Island

location_facility: Women's Care Florida / Women's Cancer Associates

location_facility: Oklahoma Cancer Specialists and Research Institute

location_facility: Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria

location_facility: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

location_facility: Seoul National University Bundang Hospital

location_facility: Oncology Clinics Victoria (OCV) - Cabrini Malvern Hospital Location

location_facility: USOR: Northwest Cancer Specialists, P.C.

location_facility: USOR: Texas Oncology - The Woodlands, Gynecologic Oncology

location_facility: FirstHealth of the Carolinas Outpatient Cancer Center

location_facility: State Autonomous Healthcare Institution Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan

location_facility: Mackay Memorial Hospital - Taipei Branch

location_facility: Mammazentrum Hamburg am Krankenhaus Jerusalem

location_facility: Grigoriev Institute for Medical Radiology NAMS of Ukraine

location_facility: USOR: Willamette Valley Cancer Institute and Research Center

location_facility: Hospital Clínico Universitario Virgen de la Arrixaca

location_facility: University Hospitals Coventry and Warwickshire

location_facility: IRCCS - Istituto Europeo di Oncologia (The European Institute of Oncology) (IEO)

location_facility: Samodzielny publiczny szpital kliniczny nr 1

location_facility: Princess Margaret Cancer Centre - University Health Network

location_facility: Burnside War Memorial Hospital - The Brian Fricker Oncology Centre

location_facility: Universitätsklinikum Carl Gustav Carus Dresden

location_facility: Centre Armoricain de radiothérapie, imagerie médicale et oncologie, CARIO

location_facility: Florida Cancer Specialist South Division

location_facility: WK Physicians Network/Gynecologic Oncology Associates

location_facility: UCLA - JCCC Dept of OBGYN - Women's Health Clinical Research Unit

location_facility: Ulm University Hospital Klinik für Frauenheilkunde und Geburtshilfe

location_facility: USOR: Texas Oncology - McAllen South Second

location_facility: University of Alabama at Birmingham (UAB) GYN Oncology

source: euctr

title: MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

summary: This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FRα. Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. Folate receptor alpha (FRα) positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.


ReferenceType: derived

ReferenceCitation: Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A, Hwang EC, Dahm P. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2021 Jun 14;6:CD009294. doi: 10.1002/14651858.CD009294.pub3.

name: Department of Preventive Medicine; College of Medicine, Chosun University; Gwangju Korea, South

family: Han

full_name: Mi Ah Han

given: Mi Ah

sequence: additional

name: Department of Urology; Rechts der Isar Medical Center, Technical University of Munich; Munich Germany

family: Maisch

full_name: Philipp Maisch

given: Philipp

name: Department of Urology; Yonsei University Wonju College of Medicine; Wonju Korea, South

name: Center of Evidence Based Medicine, Institute of Convergence Science; Yonsei University; Seoul Korea, South

family: Jung

full_name: Jae Hung Jung

given: Jae Hung

name: Department of Hematology-Oncology; Chonnam National University Medical School, Chonnam National University Hwasun Hospital; Hwasun Korea, South

family: Hwang

full_name: Jun Eul Hwang

given: Jun Eul

name: Department of Urology; University of Minnesota; Minneapolis Minnesota USA

family: Narayan

full_name: Vikram Narayan

given: Vikram

name: Velindre NHS Trust; Cardiff University Library Services; Cardiff UK

family: Cleves

full_name: Anne Cleves

given: Anne

name: Department of Urology; Chonnam National University Medical School, Chonnam National University Hwasun Hospital; Hwasun Korea, South

full_name: Eu Chang Hwang

given: Eu Chang

name: Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA

family: Dahm

full_name: Philipp Dahm

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: Cochrane Database of Systematic Reviews

publisher: Wiley

publisher_dissemination: Wiley

publisher_group: Wiley

publisher_normalized: Wiley

ipd_sharing_description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu

lead_sponsor: Janssen Research & Development, LLC

location_country:
Italy
Brazil
India
Spain
Germany
France
Czechia
Japan
Poland
Belgium
Argentina
Australia
China
United States
United Kingdom
Korea, Republic of
Taiwan

location_facility: CIMET's Inamdar Multispeciality Hospital

location_facility: Instituto COI de Pesquisa, Educacao e Gestao

location_facility: Hospital das Clinicas da Faculdade de Medicina da USP de Ribeirao Preto

location_facility: Emory University - Winship Cancer Institute

location_facility: Fondazione G. Pascale - Istituto Nazionale Tumori IRCCS

location_facility: Centro de Tratamento de Tumores Botafogo - CTTB

location_facility: Institut Universitaire du Cancer Toulouse Oncopole

location_facility: St.Marianna University School of Medicine

location_facility: CUROS - Uberörtliche urologische Gemeinschaftspraxis

location_facility: Urological Associates of Southern Arizona, P.C.

location_facility: Fondazione IRCCS Istituto Nazionale dei Tumori

location_facility: Strong Memorial Hospital University of Rochester

location_facility: Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica

location_facility: Severance Hospital, Yonsei University Health System

location_facility: Centre Hospitalier Universitaire de Nancy - Hôpital Central

location_facility: Osaka Medical and Pharmaceutical University Hospital

location_facility: The Christie NHS Foundation Trust - Christie Hospital

location_facility: Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi

location_facility: Saitama Medical University International Medical Center

location_facility: Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

location_facility: Irmandade da Santa Casa de Misericordia de Porto Alegre

location_facility: The Ohio State University- James Cancer Hospital

location_facility: Instituto de Medicina Integral Professor Fernando Figueira

location_facility: Instituto do Cancer do Estado de Sao Paulo ICESP

location_facility: Azienda Ospedaliera Universitaria Integrata Verona

location_facility: Universitätsklinikum Schleswig Holstein Campus Lübeck

location_facility: Samodzielny Publiczny Szpital Kliniczny nr 2 PUM

location_facility: Great Lakes Physician PC d/b/a Western New York Urology Associates

location_facility: University of Pittsburgh Medical Center - Cancer Centers

location_facility: Praxisklinik Urologie Rhein/Ruhr - Germany

location_facility: Kliniczny Szpital Wojewodzki nr 1 w Rzeszowie

location_facility: Medical College of Wisconsin-Froedtert Hospital

location_facility: UOC Oncologia Ospedale Provinciale di Macerata

location_facility: Hospital Araújo Jorge da Associação de Combate ao Câncer em Goiás

location_facility: Groupe Hospitalier Diaconesses Croix Saint Simon

location_facility: Kaohsiung Medical University Chung-Ho Memorial Hospital

location_facility: Kyungpook National University Chilgok Hospital

location_facility: Korea University Medical Center (KUMC) - Korea University Anam Hospital

location_facility: Meenakshi Mission Hospital and Research Center

location_facility: Rajiv Gandhi Cancer Institute & Research Centre

location_facility: South Tees Hospital NHS Foundation Trust-The James Cook University Hospital

location_facility: Renji Hospital, Shanghai Jiaotong University School of Medicine

location_facility: Tokyo Medical and Dental University Hospital

location_facility: Klinikum rechts der Isar - III. Med. Klinik und Poliklinik

location_facility: Universirty of Sheffield Teaching Hospitals NHS Trust

type: Other Identifier

title: A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions

summary: The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for participants with high-risk non-muscle-invasive bladder cancer (NMIBC) who harbor fibroblast growth factor receptor (FGFR) mutations or fusions, and who recurred after bacillus calmette-guerin (BCG) therapy.


lead_sponsor: Bristol-Myers Squibb

location_country:
Greece
Romania
Australia
Belgium
Denmark
France
Japan
Norway
Argentina
Canada
Chile
Netherlands
Ireland
Puerto Rico
China
Germany
United States
United Kingdom
Italy
Austria
Brazil
Czechia
Spain
Turkey

acronym: CheckMate 8HW

location_facility: Hospital Clinico de la Universidad De Chile

location_facility: University of California Davis Medical Center

location_facility: Hospital Universitari Germans Trias I Pujol

location_facility: Northwest Cancer Specialists (Broadway) - USOR

location_facility: Centro de Investigaciones Clinicas. Clinica Viedma S. A

location_facility: Pan American Center for Oncology Trials, LLC

location_facility: Centre Hospitalier De L'Universite De Montreal

location_facility: Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS

location_facility: Instituto Medico Especialazado Alexander Fleming

location_facility: Oncology & Hematology Associates Of Southwest Virginia, Inc.

location_facility: Landeskrankenhaus-Universitaetsklinik fuer Innere Medizin III

location_facility: University General Hospital of Heraklion

location_facility: Ordensklinikum Standort Barmherzige Schwestern

title: A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or an Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer

summary: The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.


title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

summary: The main purpose of the study is to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

ipd_sharing: No

lead_sponsor: Galderma R&D

location_country:
Italy
Germany
France
Bulgaria
Poland
Georgia
Singapore
Hungary
Belgium
Estonia
United States

location_facility:
Galderma Investigational Site 6176
Galderma Investigational Site 6230
Galderma Investigational Site 8724
Galderma Investigational Site 6168
Galderma Investigational Site 5137
Galderma Investigational Site 6185
Galderma Investigational Site 5499
Galderma Investigational Site 8807
Galderma Investigational Site 6164
Galderma Investigational Site 5407
Galderma Investigational Site 6031
Galderma Investigational Site 6048
Galderma Investigational Site 5377
Galderma Investigational Site 6251
Galderma Investigational Site 6084
Galderma Investigational Site 8719
Galderma Investigational Site 5513
Galderma Investigational Site 5021
Galderma Investigational Site 6068
Galderma Investigational Site 8825
Galderma Investigational Site 6077
Galderma Investigational Site 6133
Galderma Investigational Site 6046
Galderma Investigational Site 8224
Galderma Investigational Site 8536
Galderma Investigational Site 8704
Galderma Investigational Site 8896
Galderma Investigational Site 6169
Galderma Investigational Site 8683
Galderma Investigational Site 6145
Galderma Investigational Site 6102
Galderma Investigational Site 6142
Galderma Investigational Site 8434
Galderma Investigational Site 6144
Galderma Investigational Site 6141
Galderma Investigational Site 6135
Galderma Investigational Site 5382
Galderma Investigational Site 8226
Galderma Investigational Site 8673
Galderma Investigational Site 5442
Galderma Investigational Site 8618
Galderma Investigational Site 6115
Galderma Investigational Site 6086
Galderma Investigational Site 8745
Galderma Investigational Site 8637
Galderma Investigational Site 8823
Galderma Investigational Site 8721
Galderma Investigational Site 6235
Galderma Investigational Site 8672
Galderma Investigational Site 6049
Galderma Investigational Site 8893
Galderma Investigational Site 6171
Galderma Investigational Site 6180
Galderma Investigational Site 6124
Galderma Investigational Site 6198
Galderma Investigational Site 6236
Galderma Investigational Site 6224
Galderma Investigational Site 5567
Galderma Investigational Site 6216
Galderma Investigational Site 5448
Galderma Investigational Site 6197
Galderma Investigational Site 6040
Galderma Investigational Site 6053
Galderma Investigational Site 6079
Galderma Investigational Site 6069
Galderma Investigational Site 8003
Galderma Investigational Site 6166
Galderma Investigational Site 6151
Galderma Investigational Site 5469
Galderma Investigational Site 8906
Galderma Investigational Site 8907
Galderma Investigational Site 6143
Galderma Investigational Site 8875
Galderma Investigational Site 6080
Galderma Investigational Site 8203
Galderma Investigational Site 8747
Galderma Investigational Site 6078
Galderma Investigational Site 5362
Galderma Investigational Site 8212
Galderma Investigational Site 6147
Galderma Investigational Site 6182
Galderma Investigational Site 8866
Galderma Investigational Site 8675
Galderma Investigational Site 6150
Galderma Investigational Site 6083
Galderma Investigational Site 8523
Galderma Investigational Site 5773
Galderma Investigational Site 8799
Galderma Investigational Site 8030
Galderma Investigational Site 5031
Galderma Investigational Site 8617
Galderma Investigational Site 8839
Galderma Investigational Site 6165
Galderma Investigation Site 6228
Galderma Investigational Site 8713
Galderma Investigational Site 8692
Galderma Investigational Site 6179
Galderma Investigational Site 6081
Galderma Investigational Site 6043
Galderma Investigational Site 6044
Galderma Investigational Site 6227
Galderma Investigational Site 8577
Galderma Investigational Site 8506
Galderma Investigational Site 5140
Galderma Investigational Site 8554
Galderma Investigational Site 6029
Galderma Investigational Site 6126
Galderma Investigational Site 8656
Galderma Investigational Site 8905
Galderma Investigational Site 6038
Galderma Investigational Site 6167
Galderma Investigational Site 8820
Galderma Investigational Site 5104
Galderma Investigational Site 6130
Galderma Investigational Site 8729
Galderma Investigational Site 5367
Galderma Investigational Site 8658
Galderma Investigational Site 5707
Galderma Investigational Site 8723
Galderma Investigational Site 6181
Galderma Investigational Site 6082
Galderma Investigational Site 5566
Galderma Investigational Site 6051
Galderma Investigational Site 6234
Galderma Investigational Site 6254
Galderma Investigational Site 8808
Galderma Investigational Site 8741
Galderma Investigational Site 6162
Galderma Investigational Site 6132
Galderma Investigational Site 6096
Galderma Investigational Site 6175
Galderma Investigational Site 6034
Galderma Investigational Site 8391
Galderma Investigational Site 6067
Galderma Investigational Site 5363
Galderma Investigational Site 6052
Galderma Investigational Site 8821
Galderma Investigational Site 8705
Galderma Investigational Site 6177
Galderma Investigational Site 6136
Galderma Investigational Site 8749
Galderma Investigational Site 6097
Galderma Investigational Site 6026
Galderma Investigational Site 8727
Galderma Investigational Site 6163
Galderma Investigational Site 6041
Galderma Investigational Site 5495
Galderma Investigational Site 5482
Galderma Investigational Site 6085
Galderma Investigational Site 6045
Galderma Investigational Site 6101
Galderma Investigational Site 6063
Galderma Investigational Site 8126
Galderma Investigational Site 8667
Galderma Investigational Site 6238
Galderma Investigational Site 6062
Galderma Investigational Site 6178
Galderma Investigational Site 8706
Galderma Investigational Site 6170
Galderma Investigational Site 8733
Galderma Investigational Site 6250
Galderma Investigational Site 6114
Galderma Investigational Site 6155


ReferenceCitation: Ivanoiu A, Pariente J, Booth K, Lobello K, Luscan G, Hua L, Lucas P, Styren S, Yang L, Li D, Black RS, Brashear HR, McRae T. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies. Alzheimers Res Ther. 2016 Jun 23;8(1):24. doi: 10.1186/s13195-016-0193-y.

family: Ivanoiu

full_name: Adrian Ivanoiu

given: Adrian

sequence: first

family: Pariente

full_name: Jérémie Pariente

given: Jérémie

family: Booth

full_name: Kevin Booth

given: Kevin

family: Lobello

full_name: Kasia Lobello

given: Kasia

family: Luscan

full_name: Gerald Luscan

given: Gerald

family: Hua

full_name: Lisa Hua

given: Lisa

family: Lucas

full_name: Prisca Lucas

given: Prisca

family: Styren

full_name: Scot Styren

given: Scot

family: Yang

full_name: Lingfeng Yang

given: Lingfeng

family: Li

full_name: David Li

given: David

family: Black

full_name: Ronald S. Black

given: Ronald S.

family: Brashear

full_name: H. Robert Brashear

given: H. Robert

family: McRae

full_name: Thomas McRae

given: Thomas

currency_apc_doaj: GBP

journal_name: Alzheimer's Research & Therapy

oa_colors: green gold

oa_host_type: publisher;repository

evidence: oa journal (via doaj)

host_type: publisher

license: cc-by

license_normalized: cc-by

version: publishedVersion

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

repository_institution: PubMed Central - Europe PMC

repository_normalized: PubMed Central

evidence: oa repository (via pmcid lookup)

license_normalized: no license

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer-Nature

publisher_group: Springer-Nature

publisher_normalized: Springer

title: Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

design_allocation: Non-Randomized

status: Terminated

lead_sponsor: Pfizer

location_country:
Italy
South Africa
Chile
Sweden
Switzerland
Netherlands
Spain
Finland
France
Japan
Poland
Slovakia
Belgium
Argentina
Australia
New Zealand
United States
United Kingdom
Portugal

location_facility: National Hospital Organization Maizuru Medical Center

location_facility: Neurological Research Center of Hattiesburg Clinic

location_facility: Hospital Universitario Virgen de la Arrixaca

location_facility: The Center for Pharmaceutical Research, P.C.

location_facility: Juntendo Tokyo Koto Geriatric Medical Center

location_facility: Banner Good Samaritan Medical Center (Imaging

location_facility: Fondazione IRCCS- Istituto Neurologico Carlo Besta

location_facility: National Hospital Organization Kokura Medical Center

location_facility: National Hospital Organization Minami-Kyoto Hospital

location_facility: Associated Neurologists of Southern Connecticut, P.C.

location_facility: Fundacio ACE Institut Catala de Neurociences Aplicades

location_facility: Centre Hospitalier Universitaire Charles Nicolle

location_facility: Sezione di Neurologia - Dipartimento di Neuroscienze

location_facility: National Hospital Organization Chiba-East Hospital

location_facility: Alzheimer's Research Corp./Merician Institute for Aging

location_facility: Department de Radiologie et d'Imagerie Medicale, Hopital Pontchaillou

location_facility: National Hospital Organization Tokyo National Hospital

location_facility: Llandough Hospital, Universtity Hospital of Wales

location_facility: Samodzielny Publiczny Centralny Szpital Kliniczny

location_facility: Center for Healthy Aging, Greenwich Hospital

location_facility: Nippon Medical School Musashi Kosugi Hospital

location_facility: The McCusker Foundation for Alzheimer's Disease Research

location_facility: National Hospital Organization Hiroshima-nishi Medical Ctr.

location_facility: National Hospital Organization Minami-Okayama Medical Center

location_facility: Tokyo Metropolitan Health and Med. Treatment Co. Ebara Hosp

location_facility: CHU Nord - Hôpital Guillaume et René Laënnec

location_facility: Research Center for Clinical Studies, Inc.

location_facility: Medical University of South Carolina Hospitals and Clinics

location_facility: Memory Enhancement Center of America, Inc.

location_facility: Providence Brain Institute-Cognitive Assessment Clinic

location_facility: National Hospital Organization Matsumoto Medical Center

location_facility: Tokyo Medical University Hachioji Medical Center

location_facility: Bendheim Infusion Center, Greenwich Hospital

location_facility: Carolina Neuropsychological Services, Inc.

location_facility: Dept. of Neurosciences Charing Cross Hospital

location_facility: Unita' Operativa C - Riabilitazione Neurologica

location_facility: Memory Service North, Grenoside Grange Hospital

location_facility: Kansai Medical University Takii Hospital

location_facility: Rhode Island Mood and Memory Research Institute

location_facility: Alexian Brothers Neurosciences Institute Clinical Research

location_facility: National Hospital Organization Niigata National Hospital

location_facility: Southern Illinois University School of Medicine Department

location_facility: Nippon Medical School Chiba Hokusoh Hospital

location_facility: Palm Beach Neurological Center, Advanced Research Consultants, Inc.

location_facility: Clinical Investigation and Research Unit (CIRU)

study_completion_date_type: Actual

title: A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.

summary: The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3001(NCT00676143). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.

status_simplified: Unknown


title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).

summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.

status: Completed

ReferenceCitation: Vanassche T, Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MPA, Chen CZ, Cohen AT, Grosso MA, Medina AP, Mercuri MF, Winters SM, Zhang G, Weitz JI, Raskob GE, Büller HR. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018 Feb;162:7-14. doi: 10.1016/j.thromres.2017.12.005. Epub 2017 Dec 13.

family: Vanassche

full_name: Thomas Vanassche

family: Verhamme

full_name: Peter Verhamme

given: Peter

family: Wells

full_name: Philip S. Wells

given: Philip S.

family: Segers

full_name: Annelise Segers

given: Annelise

family: Ageno

full_name: Walter Ageno

given: Walter

family: Brekelmans

full_name: Marjolein P.A. Brekelmans

given: Marjolein P.A.

family: Chen

full_name: Cathy Z. Chen

given: Cathy Z.

family: Cohen

full_name: Alexander T. Cohen

given: Alexander T.

family: Grosso

full_name: Michael A. Grosso

given: Michael A.

family: Medina

full_name: Andria P. Medina

given: Andria P.

family: Mercuri

full_name: Michele F. Mercuri

given: Michele F.

family: Winters

full_name: Shannon M. Winters

given: Shannon M.

family: Zhang

full_name: George Zhang

given: George

family: Weitz

full_name: Jeffrey I. Weitz

given: Jeffrey I.

family: Raskob

full_name: Gary E. Raskob

given: Gary E.

family: Büller

full_name: Harry R. Büller

given: Harry R.

journal_name: Thrombosis Research

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

ReferenceCitation: Vandell AG, Walker J, Brown KS, Zhang G, Lin M, Grosso MA, Mercuri MF. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. Heart. 2017 Nov;103(22):1800-1805. doi: 10.1136/heartjnl-2016-310901. Epub 2017 Jul 8.

family: Vandell

full_name: Alexander G Vandell

given: Alexander G

family: Walker

full_name: Joseph Walker

given: Joseph

family: Brown

full_name: Karen S Brown

given: Karen S

family: Lin

full_name: Min Lin

given: Min

repository_institution: University of Oxford - Oxford Academic Notes & Queries

ReferenceCitation: Brekelmans MP, Ageno W, Beenen LF, Brenner B, Buller HR, Chen CZ, Cohen AT, Grosso MA, Meyer G, Raskob G, Segers A, Vanassche T, Verhamme P, Wells PS, Zhang G, Weitz JI. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 Sep;3(9):e437-45. doi: 10.1016/S2352-3026(16)30080-1.

ReferenceCitation: Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR; Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug;3(8):e379-87. doi: 10.1016/S2352-3026(16)30057-6. Epub 2016 Jul 1.

ReferenceCitation: Nakamura M, Wang YQ, Wang C, Oh D, Yin WH, Kimura T, Miyazaki K, Abe K, Mercuri M, Lee LH, Segers A, Büller H. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. J Thromb Haemost. 2015 Sep;13(9):1606-14. doi: 10.1111/jth.13055. Epub 2015 Aug 27.

name: Department of Cardiology and Nephrology Mie University Graduate School of Medicine Tsu Mie Japan

name: Zhongshan Hospital Fudan University ShanghaiChina

name: National Clinical Research Center of Respiratory Diseases Capital Medical University Beijing China

name: Department of Respiratory Medicine Capital Medical UniversityBeijing China

name: China‐Japan Friendship Hospital Beijing China

name: CHA Bundang Medical Center CHA University Gyeongghi‐do South Korea

name: Heart Center Cheng Hsin General HospitalTaipei Taiwan

name: Faculty of Medicine National Yang Ming University Taipei Taiwan

name: Clinical Planning Department Daiichi Sankyo Co. LtdTokyo Japan

name: Asia Development Department Daiichi Sankyo Co. LtdTokyo Japan

name: Clinical Data & Biostatistics Department Daiichi Sankyo Co. Ltd Tokyo Japan

name: Clinical Development Department Daiichi Sankyo Pharma Development Edison NJ USA

name: Department of Hematology Singapore General Hospital Singapore Singapore

name: Department of Vascular Medicine Academic Medical Center University of Amsterdam Amsterdam the Netherlands

title: Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai‐ VTE trial

ReferenceCitation: Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390.

title: Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

ReferenceCitation: Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor xa inhibitor. Drugs. 2011 Aug 20;71(12):1503-26. doi: 10.2165/11595540-000000000-00000.

repository_institution: University of Geneva - Archive ouverte UNIGE

title: Edoxaban

ipd_sharing_description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

location_country:
Australia
Belgium
Russian Federation
Denmark
Taiwan
Ukraine
India
Spain
France
Japan
Poland
Thailand
Norway
Argentina
Canada
Korea, Republic of
Turkey
South Africa
Chile
Sweden
Switzerland
Netherlands
Philippines
Singapore
Hungary
China
Germany
United States
United Kingdom
Italy
Austria
Brazil
Mexico
Czechia
Israel
New Zealand
Belarus
Estonia

location_facility:
Investigational Site 1098
Investigational Site 5015
Investigational Site 1904
Investigational Site 4470
Investigational Site 7138
Investigational Site 4509
Investigational Site 3335
Investigational Site 1007
Investigational Site 5413
Investigational Site 6135
Investigational Site 4906
Investigational Site 1910
Investigational Site 4909
Investigational Site 1200
Investigational Site 3311
Investigational Site 4324
Investigational Site 5513
Investigational Site 3023
Investigational Site 1902
Investigational Site 4009
Investigational Site 5501
Investigational Site 3613
Investigational Site 4337
Investigational Site 7128
Investigational Site 6129
Investigational Site 1109
Investigational Site 6110
Investigational Site 4702
Investigational Site 7143
Investigational Site 1076
Investigational Site 4103
Investigational Site 7115
Investigational Site 4904
Investigational Site 5412
Investigational Site 4210
Investigational Site 1050
Investigational Site 3314
Investigational Site 1300
Investigational Site 2102
Investigational Site 3903
Investigational Site 1714
Investigational Site 5706
Investigational Site 6133
Investigational Site 5400
Investigational Site 6112
Investigational Site 6150
Investigational Site 2800
Investigational Site 4704
Investigational Site 4910
Investigational Site 1712
Investigational Site 5008
Investigational Site 1032
Investigational Site 1089
Investigational Site 5510
Investigational Site 1053
Investigational Site 4320
Investigational Site 4425
Investigational Site 5202
Investigational Site 2902
Investigational Site 7109
Investigational Site 4310
Investigational Site 1701
Investigational Site 4472
Investigational Site 1035
Investigational Site 7127
Investigational Site 6003
Investigational Site 3022
Investigational Site 1012
Investigational Site 4211
Investigational Site 3341
Investigational Site 4901
Investigational Site 3313
Investigational Site 5407
Investigational Site 4318
Investigational Site 1106
Investigational Site 2915
Investigational Site 5003
Investigational Site 2903
Investigational Site 6143
Investigational Site 2914
Investigational Site 6144
Investigational Site 7132
Investigational Site 6141
Investigational Site 3027
Investigational Site 1720
Investigational Site 3508
Investigational Site 4506
Investigational Site 4000
Investigational Site 3700
Investigational Site 1040
Investigational Site 1031
Investigational Site 1718
Investigational Site 3510
Investigational Site 3608
Investigational Site 1023
Investigational Site 2006
Investigational Site 3030
Investigational Site 1048
Investigational Site 3602
Investigational Site 1038
Investigational Site 3339
Investigational Site 1017
Investigational Site 6139
Investigational Site 7004
Investigational Site 3504
Investigational Site 1024
Investigational Site 4102
Investigational Site 3318
Investigational Site 7000
Investigational Site 1069
Investigational Site 4200
Investigational Site 1039
Investigational Site 5408
Investigational Site 4008
Investigational Site 6119
Investigational Site 1711
Investigational Site 3003
Investigational Site 1033
Investigational Site 3603
Investigational Site 4419
Investigational Site 2912
Investigational Site 4402
Investigational Site 2703
Investigational Site 3611
Investigational Site 4214
Investigational Site 4405
Investigational Site 3323
Investigational Site 3615
Investigational Site 2100
Investigational Site 1602
Investigational Site 4513
Investigational Site 6145
Investigational Site 2003
Investigational Site 3900
Investigational Site 3020
Investigational Site 7001
Investigational Site 3303
Investigational Site 4213
Investigational Site 5019
Investigational Site 7135
Investigational Site 7139
Investigational Site 3509
Investigational Site 1103
Investigational Site 4110
Investigational Site 6147
Investigational Site 4420
Investigational Site 3316
Investigational Site 4802
Investigational Site 4006
Investigational Site 3904
Investigational Site 1025
Investigational Site 5401
Investigational Site 3017
Investigational Site 7154
Investigational Site 1066
Investigational Site 5005
Investigational Site 5007
Investigational Site 4443
Investigational Site 1704
Investigational Site 4424
Investigational Site 3319
Investigational Site 6113
Investigational Site 4301
Investigational Site 2702
Investigational Site 3502
Investigational Site 1304
Investigational Site 2705
Investigational Site 4308
Investigational Site 1707
Investigational Site 3607
Investigational Site 2004
Investigational Site 4315
Investigational Site 1908
Investigational Site 1700
Investigational Site 5414
Investigational Site 7005
Investigational Site 1303
Investigational Site 3024
Investigational Site 4438
Investigational Site 1706
Investigational Site 4462
Investigational Site 4104
Investigational Site 2803
Investigational Site 2804
Investigational Site 6137
Investigational Site 4912
Investigational Site 4325
Investigational Site 3028
Investigational Site 4002
Investigational Site 3004
Investigational Site 5505
Investigational Site 1042
Investigational Site 3507
Investigational Site 4451
Investigational Site 2700
Investigational Site 4306
Investigational Site 7117
Investigational Site 7125
Investigational Site 5500
Investigational Site 3500
Investigational Site 4109
Investigational Site 2900
Investigational Site 1065
Investigational site 4338
Investigational Site 4319
Investigational Site 6138
Investigational Site 4303
Investigational Site 5402
Investigational Site 3701
Investigational Site 4209
Investigational Site 1302
Investigational Site 1905
Investigational Site 4441
Investigational Site 4903
Investigational Site 4007
Investigational Site 5512
Investigational Site 1013
Investigational Site 1008
Investigational Site 3010
Investigational Site 3506
Investigational Site 1059
Investigational Site 3301
Investigational Site 1071
Investigational Site 4907
Investigational Site 1608
Investigational Site 6142
Investigational Site 2917
Investigational Site 1108
Investigational Site 6001
Investigational Site 3307
Investigational site 4801
Investigational Site 5200
Investigational Site 5702
Investigational Site 4501
Investigational Site 2906
Investigational Site 4442
Investigational Site 2704
Investigational Site 3322
Investigational Site 1901
Investigational Site 3310
Investigational Site 3327
Investigational Site 3505
Investigational Site 1719
Investigational Site 3333
Investigational Site 6104
Investigational Site 3308
Investigational Site 4317
Investigational Site 4326
Investigational Site 2904
Investigational Site 7150
Investigational Site 7144
Investigational Site 2000
Investigational Site 4430
Investigational Site 3300
Investigational Site 1004
Investigational Site 1708
Investigational Site 6105
Investigational site 1503
Investigational Site 3902
Investigational Site 4908
Investigational Site 5506
Investigational Site 7007
Investigational Site 2901
Investigational Site 3501
Investigational Site 1003
Investigational Site 1022
Investigational Site 3325
Investigational Site 5404
Investigational Site 4321
Investigational Site 7103
Investigational Site 3000
Investigational Site 7145
Investigational Site 7133
Investigational Site 1037
Investigational Site 1041
Investigational Site 6149
Investigational Site 3336
Investigational Site 5514
Investigational Site 1018
Investigational Site 3019
Investigational Site 7120
Investigational Site 1056
Investigational Site 4313
Investigational Site 6107
Investigational Site 2905
Investigational Site 5018
Investigational Site 3337
Investigational Site 4508
Investigational Site 1009
Investigational Site 3016
Investigational Site 7006
Investigational Site 4444
Investigational Site 1068
Investigational Site 3905
Investigational Site 7003
Investigational Site 7126
Investigational Site 6102
Investigational Site 1034
Investigational Site 1095
Investigational Site 3009
Investigational Site 3609
Investigational Site 1311
Investigational Site 2001
Investigational Site 5103
Investigational Site 5101
Investigational Site 3321
Investigational Site 4330
Investigational Site 3025
Investigational Site 4203
Investigational Site 4703
Investigational Site 4459
Investigational Site 1104
Investigational Site 6010
Investigational Site 1006
Investigational Site 5508
Investigational Site 6148
Investigational Site 1005
Investigational Site 5509
Investigational Site 4205
Investigational Site 2101
Investigational Site 6123
Investigational Site 4507
Investigational Site 3328
Investigational Site 1305
Investigational Site 6152
Investigational Site 7104
Investigational Site 4407
Investigational Site 4335
Investigational Site 4700
Investigational Site 1502
Investigational Site 4212
Investigational Site 3305
Investigational Site 1308
Investigational Site 2005
Investigational Site 6117
Investigational Site 5410
Investigational Site 4428
Investigational Site 1721
Investigational Site 1080
Investigational Site 1070
Investigational Site 1030
Investigational Site 4460
Investigational Site 7105
Investigational Site 3312
Investigational Site 1049
Investigational Site 6130
Investigational Site 4328
Investigational Site 4100
Investigational Site 1058
Investigational Site 7146
Investigational Site 4003
Investigational Site 1036
Investigational Site 1204
Investigational Site 5902
Investigational Site 5409
Investigational Site 1057
Investigational Site 7106
Investigational Site 3329
Investigational Site 5203
Investigational Site 3503
Investigational Site 1110
Investigational Site 1093
Investigational Site 2911
Investigational Site 6146
Investigational Site 5105
Investigational Site 2802
Investigational Site 4515
Investigational Site 6132
Investigational Site 1301
Investigational Site 5014
Investigational Site 4010
Investigational Site 5403
Investigational Site 2007
Investigational Site 4905
Investigational Site 3612
Investigational Site 4327
Investigational Site 6114
Investigational Site 1715
Investigational Site 5503
Investigational Site 1100
Investigational site 2701
Investigational Site 4302
Investigational Site 7152
Investigational Site 2910
Investigational Site 3302
Investigational Site 7123
Investigational Site 5405
Investigational Site 5900
Investigational Site 5104
Investigational Site 1002
Investigational Site 4409
Investigational Site 1312
Investigational Site 5703
Investigational Site 4001
Investigational Site 1047
Investigational Site 4206
Investigational Site 1019
Investigational Site 4207
Investigational Site 7122
Investigational Site 7147
Investigational Site 3617
Investigational Site 4900
Investigational Site 3029
Investigational Site 4800
Investigational Site 4316


title: An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis

acronym: CONSONANCE

summary: This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).

ipd_sharing_description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

lead_sponsor: Hoffmann-La Roche

location_country:
Guatemala
Russian Federation
Denmark
Costa Rica
Morocco
France
Panama
Poland
Canada
Colombia
United Arab Emirates
Saudi Arabia
Netherlands
Hungary
Ireland
Germany
United States
Italy
Brazil
Bosnia and Herzegovina
Lebanon
Mexico
Czechia
Egypt
Spain

location_facility: Uniwersytecki Szpital Kliniczny w Bialymstoku

location_facility: Aarhus Universitetshospital, Neurologisk Afd. F, Skleroseklinikken

location_facility: ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla

location_facility: AOU Città della Salute e della Scienza; Neurologia 1

location_facility: Grupo Medico de Investigacion Clinica Multidisciplinaria

location_facility: Azienda Ospedaliero Universitaria Consorziale Policlinico di; Scienze Neurologiche

location_facility: Beaumont Hospital; Clinical Research and Education Centre, Smurfit Building

location_facility: Università degli Studi della Campania Luigi Vanvitelli; Dip. Ass. Integrato Med Int-II Clinica Neur

location_facility: Hospital Vall d'Hebron; Servicio de Neurología

location_facility: Universitätsmedizin Greifswald; Klinik und Poliklinik für Neurologie

location_facility: AOUC Azienda Ospedaliero-Universitaria Careggi; Neurologia 2

location_facility: University of Chicago; Neurology/MC 2030

location_facility: Azienda Ospedaliera di Padova; Clinica Neurologica

location_facility: Centre Hospitalier Universitaire de Rennes

location_facility: NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH

location_facility: Hospital Universitario la Fe; Servicio de Neurologia

location_facility: London Health Sciences Centre Uni Campus

location_facility: King Fahad Medical City; Gastroentrology

location_facility: Azienda Sanitaria Ospedaliera S. Luigi Gonzaga; Centro Regionale Sclerosi Multipla - Neurologia II

location_facility: A.O. Sant'Andrea; UOC Neurologia, Dip. di Neuroscienze, Salute Mentale e Organi di Senso (NESMOS)

location_facility: Hospital das Clínicas Faculdades Médicas de Ribeirão Preto

location_facility: Wojskowy Instytut Medyczny Centralny Szpital Kliniczny MON

location_facility: Hopital Militaire d'Instruction Mohamed V

location_facility: Fundacion Clinica Valle del Lili; Unidad de Investigaciones Clinicas

location_facility: Fakultní Nemocnice Olomouc; Neurologicka Klinika

location_facility: Zuyderland Medisch Centrum - Sittard Geleen

location_facility: University of British Columbia Hospital; Division of Neurology

location_facility: Azienda Ospedaliera Sant'Andrea; UOC Neurologia

location_facility: St Vincents University Hospital; Carew House-Neurology Department

location_facility: Università degli studi della Campania Luigi Vanvitelli; Dip.Ass Int Med Int-I Clinica Neurologica

location_facility: IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla

location_facility: Ospedale Binaghi; Centro Sclerosi Multipla

location_facility: CHU De Caen; Service De Neurologie Dejerine

location_facility: Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B

location_facility: AOU Careggi; Neurologia 1-Dip. Neuroscienze Psicologia Area Farmaco Salute del Bambino(NEUROFARBA)

location_facility: Nemocnice Jihlava; NEU-Neurologicke oddeleni

location_facility: Ospedale S.Antonio Abate; Neurologia 2 - Sclerosi Multipla e Recupero Neurologico

location_facility: Rigshospitalet; Neurologisk Klinik Glostrup

location_facility: Groupe Hospitalo-Universitaire Caremeau; Service Neurologie

location_facility: A. O. U. Federico II; Dip Neuroscienze, Scienze Riproduttive ed Odontostomatologiche

location_facility: Ain Shams University Hospital; Clinical Research Center (MASRI-CRC)

location_facility: University of Cincinnati; Department of Neurology

location_facility: King Faisal Specialist Hospital & Research Centre; Oncology

location_facility: Pécsi Tudományegyetem, Klinikai Központ Neurológiai Klinika; Klinikai Központ Neurológiai Klinika

location_facility: Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla

location_facility: VALEOMED Diagnosztikai Központ; VALEOMED Diagnosztikai Központ

location_facility: City Clinical Hospital #24; Multipal Sclerosis department

location_facility: American University of Beirut - Medical Center

location_facility: Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie

location_facility: Ospedale Cattinara; Amb Studio Sclerosi Multipla, Clinica Neurlogica

location_facility: Lebanese American University Medical Center- Rizk Hospial

location_facility: Washington University School of Medicine

location_facility: Hospital das Clinicas - FMUSP_X; Neurologia

location_facility: Universitätsklinikum "Carl Gustav Carus", Zentrum für Klinische Neurowissenschaften

location_facility: SP Swiecickiego UM Marcinkowskiego; Od. Klin. Neurologii z podod. Udarowym

location_facility: Vseobecna fakultni nemocnice v Praze; MS Centrum, Neurologicka klinika

location_facility: Clinical Research Center-Alex university; Neurology Department

location_facility: Centre Hospitalier Universitaire Hassan II

location_facility: Semmelweis Egyetem AOK; Neurologiai Klinika

location_facility: Hopital Civil de Strasbourg; Service de Neurologie

location_facility: Groupe Hospitalier Pellegrin; Service de Neurologie - 3ème étage

location_facility: AOU Policlinico V. Emanuele - P.O G. Rodolico; Clinica Neurologica, Centro Sclerosi Multipla

location_facility: Fraser Health Authority - Fraser Health Multiple Sclerosis

location_facility: Unidad de investigacion en salud (UIS); Neurociencias

location_facility: Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz

location_facility: National Center of Social Significant Disease

location_facility: Hospital Universitario Virgen de Arrixaca; Servicio de Neurología

location_facility: Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari

location_facility: Krankenhaus Martha-Maria Hallo-Dölau, Klinik für Neurologie

location_facility: Hospital Notre-Dame du Centre Hospitalier de l'Universite de Montreal

location_facility: Vladimirskiy Regional Scientific Research Inst.

location_facility: Wayne State University School of Medicine

location_facility: Policlinico Universitario A. Gemelli; UOC Neurologia - Centro Sclerosi Multipla

location_facility: Deutsche Klinik für Diagnostik; DKD Helios Klinik Wiesbaden, Abt. Neurologie

location_facility: University Clinical Center of the Republic of Srpska; Neurology Clinic

location_facility: Yale University Multiple Sclerosis Center

location_facility: IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla

location_facility: Clinical Center University of Sarajevo; Neurology clinic

location_facility: CHU de la Timone - Hopital d Adultes; Service de Neurologie

location_facility: University Hospital Mostar; Neurology Clinic

location_facility: Massachusetts General Hospital; Neurological Clinical Research Institute (NCRI)

location_facility: Scientific Neurology Center; Neurological department #6

location_facility: Policlinico G.B. Rossi; Dip. Scienze Neurologiche Biomediche - Neurologia B - Amb. Sclerosi Multipla

location_facility: Rigshospitalet; Skleroseklinikken - Glostrup

location_facility: Szpital Uniwersytecki w Krakowie; Oddział kliniczny Neurologii

location_facility: University Clinical Center Tuzla; Neurology

location_facility: IRCCS Istituto Neurologico C. Mondino-Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla


location_country:
Peru
Finland
Greece
Romania
Australia
Denmark
Spain
Croatia
France
Japan
Poland
Thailand
Norway
Korea, Republic of
Turkey
Colombia
Chile
Switzerland
Netherlands
Bulgaria
Hungary
Ireland
Portugal
Germany
United Kingdom
Italy
Austria
Brazil
Mexico
Cyprus
Czechia
Israel
Kazakhstan
Estonia
Latvia

acronym: CUPISCO

location_facility: Universitätsklinikum Augsburg; II. Med. Klinik

location_facility: Instituto Nacional de Enfermedades Neoplasicas

location_facility: Institut Catala d Oncologia Hospital Duran i Reynals

location_facility: Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.

location_facility: Kantonsspital Graubünden Medizin Onkologie; Onkologie und Hämatologie

location_facility: Policlinico Univ. - A.O. Mater Domini; U.O. Di Oncoematologia

location_facility: National Hospital Organization Kyushu Cancer Center

location_facility: Akdeniz University Medical Faculty; Medical Oncology Department

location_facility: Arcispedale Santa Maria Nuova; Oncologia

location_facility: Hammersmith Hospital; Garry Weston Centre

location_facility: Istanbul University Cerrahpaşa-Cerrahpaşa Medical Faculty; Medikal Onkoloji Departmani

location_facility: Hospital Quiron de Madrid; Servicio de Oncologia

location_facility: Royal United Hospital; Oncology Department

location_facility: Klinikum der LMU München, Campus Großhadern, Krebszentrum München; Comprehensive Cancer Center LMU

location_facility: Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly

location_facility: Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik

location_facility: Uzsoki Utcai Korhaz; Onkoradiológiai Osztály

location_facility: UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie

location_facility: Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck

location_facility: Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine

location_facility: Theagenio Anticancer Hospital; 3Rd Oncology Clinic

location_facility: Univ General Hosp Heraklion; Medical Oncology

location_facility: Instituto Nacional de Cancer - INCa; Oncologia

location_facility: Fakultni nemocnice Olomouc; Onkologicka klinika

location_facility: Hospital Nacional Cayetano Heredia; Hematology - Oncology

location_facility: Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii

location_facility: Hospital Universitari i Politecnic La Fe; Oncologia

location_facility: Ramathibodi Hospital; Medicine/Oncology; Clinical Research Center

location_facility: Hacettepe Uni Medical Faculty Hospital; Oncology Dept

location_facility: Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont

location_facility: CRLCC-Francois Baclesse; Oncologie Médicale

location_facility: Western General Hospital; Edinburgh Cancer Center

location_facility: A.O. UNIVERSITARIA S. LUIGI GONZAGA; Oncologia Medica

location_facility: Fundacion Clinica Valle del Lili; Unidad de Investigaciones Clinicas

location_facility: St Vincent'S Uni Hospital; Medical Oncology

location_facility: Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Internistische Onkologie / Haematologie

location_facility: James Lind Centro de Investigación Del Cáncer

location_facility: IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima

location_facility: Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi

location_facility: Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.

location_facility: University College London Hospitals NHS Foundation Trust - University College Hospital

location_facility: Complejo Hospitalario de Navarra; Servicio de Oncologia

location_facility: Hospital Universitario 12 de Octubre; Servicio de Oncologia

location_facility: Hospital Universitario Virgen Macarena; Servicio de Oncologia

location_facility: Universitätsklinikum Heidelberg;Innere Medizin V, Hämatologie/Onkologie

location_facility: Universitätsklinikum Frankfurt, UCT; Universitäres Centrum für Tumorerkrankungen

location_facility: Hospital Sant Joan Despi- Moises Broggi; Servicio de Oncologia

location_facility: Universitätsklinikum Düsseldorf; Klinik für Hämatologie, Onkologie und Klinische Immunologie

location_facility: Hospital Clinico San Carlos; Servicio de Oncologia

location_facility: SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm.

location_facility: Kazakh Scientific Research Institution Of Oncology and Radiology; Chemotherapy department

location_facility: North Estonia Medical Centre, Oncology and hematology Clinic; Department of Chemotherapy

location_facility: Ankara University Medical Faculty; Medikal Onkoloji

location_facility: Multidisciplinary medical center; Chemotherapy department

location_facility: Helse Stavanger HF, Stavanger Universitetssjukehus; Klinikk for Blod og kreftsykdommer

location_facility: Asst Papa Giovanni XXIII; Oncologia Medica

location_facility: ohO - ostholstein ONKOLOGIE; Dres.Gerdt Hübner/Clemens Engels (Oldenburg)/Yael Bonnin-Gruber (Eutin)

location_facility: Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica

location_facility: Universitätsklinikum Jena, Klinik für Innere Medizin II; Hämatologie und Internistische Onkologie

location_facility: U. O. Oncologia Medica, Ospedale Santa Chiara

location_facility: Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Oddzial Badan Wczesnych Faz

location_facility: IPO do Porto; Servico de Oncologia Medica

location_facility: Irccs Ospedale San Raffaele;Oncologia Medica

location_facility: Hospital Ramon y Cajal; Servicio de Oncologia

location_facility: Tampere University Hospital; Dept of Oncology

location_facility: Chaim Sheba medical center, Oncology division

location_facility: Complexo Hospitalario de Vigo. Hospital Álvaro Cunqueiro; Servicio de Oncología

location_facility: Centre Eugene Marquis; Service d'oncologie

location_facility: Hospital Clínic i Provincial; Servicio de Oncología

location_facility: National Hospital Organization Shikoku Cancer Center

location_facility: Universitätsklinikum Münster, Medizinische Klinik A, Translationale Onkologie

location_facility: Institutul Regional de Oncologie Iasi; Clinica de Hematologie

location_facility: Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika

location_facility: Uni Hospital of Ioannina; Oncology Dept.

location_facility: Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Chemotherapie & Infektionskrankhei

location_facility: Severance Hospital, Yonsei University Health System; Oncology

location_facility: Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; Oncologie Medicala

location_facility: Multiprofile Hospital for Active Treatment Uni Hospital; Department of medicinal oncology

location_facility: Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology

location_facility: Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden

location_facility: LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie

location_facility: Centre Jean Perrin Centre Regional de Lutte Contre Le Cancer D auvergne

location_facility: Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika

location_facility: Rabin MC; Davidof Center - Oncology Institute

location_facility: Aarhus Universitetshospital, Afdeling for Eksperimentel Klinisk Onkologi

location_facility: Hospital Universitario Miguel Servet; Servicio Oncologia

location_facility: Helsinki University Central Hospital; Dept of Oncology

location_facility: Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology

location_facility: Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia

location_facility: Klinikum Mannheim III. Medizinische Klinik

location_facility: Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas

location_facility: Institut Paoli-Calmettes; Oncologie Medicale 1

location_facility: Riga East Clinical University Hospital Latvian Oncology Centre

location_facility: Debreceni Egyetem Klinikai Kozpont ; Department of Oncology

location_facility: Universitätsklinikum Hamburg-Eppendorf, Onkologisches Zentrum, Studienzentrale der II. Med. Klinik

location_facility: Instituto do Cancer do Estado de Sao Paulo - ICESP

location_facility: Onkologisches Zentrum - Onkologie Dachau

location_facility: Oslo universitetssykehus HF, Ullevål, Kreftsenteret

location_facility: Waterford Regional Hospital; Department Of Medical Oncology

location_facility: Istituto Nazionale Tumori Fondazione G. Pascale

location_facility: Inst. Nacional de Cancerologia; Clinica de Seno

title: A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy

summary: This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy.


title: A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa)

summary: The primary objective of the trial is to investigate the effect of the use of inhaled colistimethate sodium, administered twice daily via the I-neb for 12 months, compared to placebo in subjects with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with P. aeruginosa on the frequency of pulmonary exacerbations.

primary_purpose: Prevention

lead_sponsor: Zambon SpA

location_country:
Italy
United States
Germany
France
Poland
Greece
Israel
Argentina
Australia
New Zealand
Portugal
Canada

location_facility:
Zambon Investigatiev Site
Zambon investigative Site
ZambonInvestigative Site
Zambon Investigative Site
Zambon Investgative Site


title: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

acronym: HIMALAYA

summary: This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy.

lead_sponsor: AstraZeneca

location_country:
Italy
Brazil
India
Hong Kong
Spain
Vietnam
Germany
France
Japan
Korea, Republic of
Thailand
Russian Federation
China
United States
Canada
Taiwan
Ukraine